Results 51 to 60 of about 5,215,493 (360)

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. [PDF]

, 2017
BackgroundT cells engineered to express chimeric antigen receptors (CARs) have established efficacy in the treatment of B-cell malignancies, but their relevance in solid tumors remains undefined.
A Molinolo, A Stasi Di, A Thor, B Fisher, BA Irving, BL Levine, C Romeo, CC Kloss, CY Wu, D Moritz, DL Porter, DW Lee, F Guadagni, HM Finney, I Blanco, I Stancovski, J Scholler, JD Wolchok, JL Murray, JN Kochenderfer, JW Greiner, KD Griffith, L Naldini, M Hegde, M Kalos, ME Dudley, MH Finer, MH Kershaw, ML Davila, MR Lander, N Gonzales, NP Restifo, P Hwu, RA Morgan, RE Walker, RF Meredith, RP McGuinness, RT Mitsuyasu, S Guedan, SD Patel, SG Deeks, SL Maude, SV Kashmiri   +42 more
core   +1 more source

Hematopoietic (stem) cells—The elixir of life?

FEBS Letters, EarlyView.
The aging of HSCs (hematopoietic stem cells) and the blood system leads to the decline of other organs. Rejuvenating aged HSCs improves the function of the blood system, slowing the aging of the heart, kidney, brain, and liver, and the occurrence of age‐related diseases.
Emilie L. Cerezo, Jonah Anderson, Emilie Dinh Vedrenne, Noël Yeh Martín, Jette Lengefeld   +4 more
wiley   +1 more source

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer

Cancer Medicine, 2020
Background Mismatch repair proficient (MMRp) colorectal cancer (CRC) has been refractory to single‐agent programmed cell death protein 1 (PD1) inhibitor therapy.
Mark Yarchoan, Chiung‐Yu Huang, Qingfeng Zhu, Anna K. Ferguson, Jennifer N. Durham, Robert A. Anders, Elizabeth D. Thompson, Noah S. Rozich, Dwayne L. Thomas II, Julie M. Nauroth, Christina Rodriguez, Arsen Osipov, Ana De Jesus‐Acosta, Dung T. Le, Adrian G. Murphy, Daniel Laheru, Ross C. Donehower, Elizabeth M. Jaffee, Lei Zheng, Nilofer S. Azad   +19 more
doaj   +1 more source

Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target

Experimental Hematology & Oncology, 2023
Immunotherapy has emerged as an effective treatment for various types of cancers. Recent studies have highlighted a significant correlation between the gut microbiome and patients’ response to immunotherapy. Several characteristics of the gut microbiome,
Mengwei Zhang, Jinkai Liu, Q. Xia
semanticscholar   +1 more source

The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC [PDF]

, 2017
Background: Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic
Abdel-Rahman, Aguiar, Borghaei, Brahmer, Calhoun, Chen, Dent, Domingues, Doyle, Ferlay, Goeree, Hanahan, Herbst, Herbst, Huang, Hurvitz, Masters, Matter-walstra, Moro-Sibilot, Nafees, Passiglia, Petitti, Rittmeyer, Siegel, Stokes, Tartari   +25 more
core   +3 more sources

The role of histone modifications in transcription regulation upon DNA damage

FEBS Letters, EarlyView.
This review discusses the critical role of histone modifications in regulating gene expression during the DNA damage response (DDR). By modulating chromatin structure and recruiting repair factors, these post‐translational modifications fine‐tune transcriptional programmes to maintain genomic stability.
Angelina Job Kolady, Siyao Wang
wiley   +1 more source

Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer

Journal for ImmunoTherapy of Cancer, 2019
Background Cancer immunotherapies are emerging as promising treatment strategies for ovarian cancer patients that experience disease relapse following first line therapy.
A. J. Robert McGray, Ruea-Yea Huang, Sebastiano Battaglia, Cheryl Eppolito, Anthony Miliotto, Kyle B. Stephenson, Amit A. Lugade, Gill Webster, Brian D. Lichty, Mukund Seshadri, Danuta Kozbor, Kunle Odunsi   +11 more
doaj   +1 more source

Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy

Cell Death and Disease
The interplay between extracellular matrix (ECM) stiffness and the tumor microenvironment is increasingly recognized as a critical factor in cancer progression and the efficacy of immunotherapy.
Zizhao Mai, Yunfan Lin, Pei Lin, Xinyuan Zhao, Li Cui   +4 more
semanticscholar   +1 more source

Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy

Signal Transduction and Targeted Therapy, 2021
Despite great success in cancer immunotherapy, immune checkpoint-targeting drugs are not the most popular weapon in the armory of cancer therapy. Accumulating evidence suggests that the tumor immune microenvironment plays a critical role in anti-cancer ...
Tianyu Tang, Xing Huang, Gang Zhang, Zhengtao Hong, X. Bai, T. Liang   +5 more
semanticscholar   +1 more source

Antigen-Specific Polyclonal Cytotoxic T Lymphocytes Induced by Fusions of Dendritic Cells and Tumor Cells [PDF]

, 2010
The aim of cancer vaccines is induction of tumor-specific cytotoxic T lymphocytes (CTLs) that can reduce the tumor mass. Dendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune ...
Gong, Jianlin, Hara, Eiichi, Homma, Sadamu, Koido, Shigeo, Namiki, Yoshihisa, Ohkusa, Toshifumi, Tajiri, Hisao   +6 more
core   +5 more sources